Although the definition of the phenotype is imprecise, cardiometabolic syndrome (CMS) includes a constellation of complex diseases such as type 2 diabetes, dislipidemias, central obesity and hypertension, proinflammatory and prothrombotic states, ovarian polycystosis and fatty liver. The genetics of each disease is complex in itself and varies in spectrum from monogenic and syndromic models of inheritance, usually rare, to the most common polygenic and multifactorial forms. In addition, human studies using the candidate-gene approach indicate that common genetic variants of several genes are associated with the development of CMS. Genome-wide scans have also provided several chromosomal regions associated with some of the components of CMS. In addition, through comparative genomics animal models can generate a map for candidate loci in humans and a promising approach is offered by bioinformatic tools for gene prioritization. Lastly, the involvement of genes whose products are already the targets for approved drugs, such as SLC6A4, PPARα and PPARγ , in the development of CMS suggests new avenues for CMS pharmacological treatment.
Adie, E.A. et al. (2006) SUSPECTS: enabling fast and effective prioritization of positional candidates, Bioinformatics22: 773—774.
2.
Aerts, S. et al. (2006) Gene prioritization through genomic data fusion, Nat Biotechnol24: 537—544.
3.
Alberti, K.G. et al. (2005) The metabolic syndrome — a new worldwide definition, Lancet366: 1059—1062.
4.
Alberti, K.G., Zimmet, P.Z. (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation, Diabet Med15: 539—553.
5.
Altshuler, D. et al. (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes, Nat Genet26: 76—80.
6.
Andersen, G. et al. (2006) Studies of the association of the GNB3 825C> T polymorphism with components of the metabolic syndrome in white Danes, Diabetologia49: 75—82.
7.
Arya, R. et al. (2002) Factors of insulin resistance syndrome — related phenotypes are linked to genetic locations on chromosomes 6 and 7 in nondiabetic mexican—americans, Diabetes51: 841—847.
8.
Barker, D.J. et al. (1990) Fetal and placental size and risk of hypertension in adult life, Br Med J301: 259—262.
9.
Binder, A. (2007) A review of the genetics of essential hypertension , Curr Opin Cardiol22: 176—184.
Chinetti-Gbaguidi, G. et al. (2005) Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy, Curr Opin Pharmacol5: 177—183.
12.
Connolly, H.M. et al. (1997) Valvular heart disease associated with fenfluramine—phentermine , N Engl J Med337: 581—588.
13.
Costa, L.A. et al. (2002) The ACE insertion/deletion polymorphism is not associated with the metabolic syndrome (WHO Definition) in Brazilian type 2 diabetic patients, Diabetes Care25: 2365—2366.
14.
Cowley, A.W. (2006) The genetic dissection of essential hypertension , Nat Rev Genet7: 829—840.
15.
Despres, J.P. and Lemieux, I. (2006) Abdominal obesity and metabolic syndrome, Nature444: 881—887.
16.
Desvergne, B. and Wahli, W. (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism, Endocr Rev20: 649—688.
17.
Di, M. et al. (2004) The endocannabinoid system and its therapeutic exploitation, Nat Rev Drug Discov3: 771—784.
18.
Dina, C. et al. (2007) Comment on “A common genetic variant is associated with adult and childhood obesity”, Science315: 187.
19.
Dubern, B. et al. (2001) Mutational analysis of melanocortin-4 receptor, agouti-related protein, and alpha—melanocyte—stimulating hormone genes in severely obese children, J Pediatr139: 204—209.
20.
Erkkila, A.T. et al. (2002) Variation in the fatty acid binding protein 2 gene is not associated with markers of metabolic syndrome in patients with coronary heart disease, Nutr Metab Cardiovasc Dis12: 53—59.
Farooqi, I.S. et al. (2003) Clinical Spectrum of Obesity and Mutations in the Melanocortin 4 Receptor Gene, N Engl J Med348: 1085.
23.
Ford, E.S. et al. (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey, J Am Med Assoc287: 356—359.
24.
Francis, G.A. et al. (2006) Peroxisomal proliferator activated receptor—gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3), BMCMed Genet7: 3.
25.
Gemma, C. et al. (2006) Mitochondrial DNA Depletion in Small— and Large—for—Gestational— Age Newborns, Obesity (Silver Spring) 14: 2193—2199.
26.
Guettier, J.M. et al. (2005) Polymorphisms in the fatty acid—binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population, J Clin Endocrinol Metab90: 1705—1711.
27.
Hainer, V. et al. (2006) Serotonin and norepinephrine reuptake inhibition and eating behavior, Ann NY Acad Sci1083: 252—269.
28.
Hegele, R.A. (2001) Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism, Am J Hum Genet69: 1161—1177.
29.
Hegele, R.A. (2005) Genetic and physiological insights into the metabolic syndrome, Am J PhysiolRegul Integr Comp Physiol289: R663—R669.
30.
Hegele, R.A. et al. (2001) Common genomic variation in LMNA modulates indexes of obesity in Inuit, J Clin Endocrinol Metab86: 2747—2751.
31.
Heils, A. et al. (1996) Allelic variation of human serotonin transporter gene expression, J Neurochem66: 2621—2624.
32.
Herbert, A. et al. (2006) A common genetic variant is associated with adult and childhood obesity, Science312: 279—283.
33.
Hotamisligil, G.S. (2003) Inflammatory pathways and insulin action, Int J Obes Relat Metab Disord27(Suppl 3): S53—S55.
34.
Hotamisligil, G.S. (2006) Inflammation and metabolic disorders, Nature444: 860—867.
35.
Kahn, R. (2007) Metabolic syndrome: is it a syndrome? Does it matter?Circulation115: 1806—1810.
36.
Kajantie, E. (2006) Fetal origins of stress-related adult disease, Ann NY Acad Sci1083: 11—27.
37.
Kelley, D.E. et al. (2002) Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes, Diabetes51: 2944—2950.
38.
Kissebah, A.H. et al. (2000) Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome, Proc Natl Acad Sci USA97: 14478—14483.
39.
Kyrou, I. et al. (2006) The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome, Ann NY Acad Sci1083: 270—305.
40.
Langefeld, C.D. et al. (2004) Linkage of the metabolic syndrome to 1q23—q31 in Hispanic families: the Insulin Resistance Atherosclerosis Study Family Study, Diabetes53: 1170—1174.
41.
Lee, H.K. et al. (2005) Mitochondria-based model for fetal origin of adult disease and insulin resistance, Ann NY Acad Sci1042: 1—18.
42.
Lee, Y.J. and Tsai, J.C. (2002) ACE gene insertion/ deletion polymorphism associated with 1998 World Health Organization definition of metabolic syndrome in Chinese type 2 diabetic patients, Diabetes Care25: 1002—1008.
43.
Loos, R.J. et al. (2003) Genome-wide linkage scan for the metabolic syndrome in the HERITAGE Family Study, J Clin Endocrinol Metab88: 5935—5943.
44.
Loos, R.J. et al. (2007) Comment on “A common genetic variant is associated with adult and childhood obesity”, Science315: 187.
45.
Lopez-Bigas, N. and Ouzounis, C.A. (2004) Genome-wide identification of genes likely to be involved in human genetic disease, Nucleic Acids Res32: 3108—3114.
46.
Mani, A. et al. (2007) LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science315: 126—128.
47.
Martin, S., Nicaud, V. et al. (2003) Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges, Biochim Biophys Acta1637: 217—225.
48.
Mein, C.A. et al. (2005) Selection of candidate genes in hypertension, MethodsMol Med108: 107—129.
49.
Meirhaeghe, A. et al. (2005) Lack of association between certain candidate gene polymorphisms and the metabolic syndrome, Mol Genet Metab86: 293—299.
50.
Miller, M. et al. (2007) APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome, Arch Med Res38: 444—451.
51.
Mootha, V.K. et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , Nat Genet34: 267—273.
52.
Muller, T.D. et al. (2007) No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents, Mol Genet Metab90: 429—434.
53.
Multiple authors (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls, Nature447: 661—678.
54.
Mutch, D.M. and Clement, K. (2006) Unraveling the genetics of human obesity, PLoS Genet2: e188.
55.
Nathan, D.M. (2007) Rosiglitazone and Cardiotoxicity — Weighing the Evidence, N Engl J Med.
56.
Ncep. (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), J Am Med Assoc285: 2486—2497.
57.
Neve, B.P. et al. (2000) Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis, Biochem Pharmacol60: 1245—1250.
58.
Nisoli, E. et al. (2007) Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome?Circ Res100: 795—806.
59.
Olivieri, O. et al. (2003) Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease, J Lipid Res44: 2374—2381.
60.
Pausova, Z. et al. (2000) Role of tumor necrosis factor-alpha gene locus in obesity and obesity-associated hypertension in French Canadians, Hypertension36: 14—19.
61.
Perez-Iratxeta, C. et al. (2002) Association of genes to genetically inherited diseases using data mining, Nat Genet31: 316—319.
62.
Pollex, R.L. et al. (2006) Metabolic syndrome in aboriginal Canadians: prevalence and genetic associations, Atherosclerosis184: 121—129.
63.
Porter, J.R. and Barrett, T.G. (2005) Monogenic syndromes of abnormal glucose homeostasis: clinical review and relevance to the understanding of the pathology of insulin resistance and beta cell failure, J Med Genet42: 893—902.
64.
Pravenec, M. and Kurtz, T.W. (2007) Molecular genetics of experimental hypertension and the metabolic syndrome: from gene pathways to new therapies, Hypertension49: 941—952.
65.
Redon, R. et al. (2006) Global variation in copy number in the human genome, Nature444: 444—454.
66.
Russo, P. et al. (2007) Genetic Variations at the Endocannabinoid Type 1 Receptor Gene (CNR1) Are Associated with Obesity Phenotypes in Men , J Clin Endocrinol Metab92: 2382—2386.
67.
Saxena, R. et al. (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels, Science316: 1331—1336.
68.
Schoonjans, K. et al. (1996) PPARalpha and PPARgamma activators direct a distinct tissuespecific transcriptional response via a PPRE in the lipoprotein lipase gene, EMBO J15: 5336—5348.
69.
Schupp, M. et al. (2005) Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity, Diabetes54: 3442—3452.
70.
Scott, L.J. et al. (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants, Science316: 1341—1345.
71.
Shih, D.Q. and Stoffel, M. (2002) Molecular etiologies of MODY and other early-onset forms of diabetes, Curr Diab Rep2: 125—134.
72.
Siffert, W. (2005) G protein polymorphisms in hypertension, atherosclerosis, and diabetes, Annu Rev Med56: 17—28.
73.
Smith, A.J. et al. (2007) INSIG2 gene polymorphism is not associated with obesity in Caucasian, Afro-Caribbean and Indian subjects, Int J Obes (Lond).
74.
Sonnenberg, G.E. et al. (2004) A novel pathway to the manifestations of metabolic syndrome, Obes Res12: 180—186.
75.
Sookoian, S. et al. (2005a) Peroxisome proliferator-activated receptor gamma and its coactivator-1 alpha may be associated with features of the metabolic syndrome in adolescents, J Mol Endocrinol35: 373—380.
76.
Sookoian, S. et al. (2005b) The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with hypertension in adolescents harboring the metabolic syndrome, Am J Hypertens18: 1271—1275.
77.
Sookoian, S. et al. (2005c) Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome , Obes Res13: 2122—2131.
78.
Sookoian, S. et al. (2007) Short allele of serotonin transporter gene promoter is a risk factor for obesity in adolescents, Obesity (Silver Spring) 15: 271—276.
79.
Stancakova, A. et al. (2006) Effect of gene polymorphisms on lipoprotein levels in patients with dyslipidemia of metabolic syndrome, Physiol Res55: 483—490.
80.
Stoll, M. et al. (2000) New target regions for human hypertension via comparative genomics, Genome Res10: 473—482.
81.
Tenenbaum, A. et al. (2005) Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons, Cardiovasc Diabetol4: 14.
82.
Turek, F.W. et al. (2005) Obesity and metabolic syndrome in circadian Clock mutant mice, Science308: 1043—1045.
83.
van Driel, M.A. et al. (2005) GeneSeeker: extraction and integration of human disease-related information from web-based genetic databases, Nucleic Acids Res33: W758—W761.
84.
Vimaleswaran, K.S. et al. (2006) Thr54 allele carriers of the Ala54Thr variant of FABP2 gene have associations with metabolic syndrome and hypertriglyceridemia in urban South Indians, Metabolism55: 1222—1226.
85.
Weiss, R. et al. (2004) Obesity and the metabolic syndrome in children and adolescents, N Engl J Med350: 2362—2374.
86.
Yamamoto, M. et al. (2004) Association of GNB3 gene with pulse pressure and clustering of risk factors for cardiovascular disease in Japanese, Biochem Biophys Res Commun316: 744—748.
87.
Yumuk, V.D. (2006) Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome proliferator-activated receptors, Ann NY Acad Sci1083: 306—318.
88.
Zeggini, E. et al. (2007) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes, Science316: 1336—1341.
